These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 35930018)

  • 1. Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial.
    Zhang X; Ren H; Zhao C; Shi Z; Qiu L; Yang F; Zhou X; Han X; Wu K; Zhong H; Li Y; Li J; Ji L
    Diabetologia; 2022 Oct; 65(10):1613-1626. PubMed ID: 35930018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment.
    Wang Z; Wang J; Hu J; Chen Y; Dong B; Wang Y
    Life Sci; 2021 Jun; 274():119069. PubMed ID: 33460667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
    Pan C; Yang W; Barona JP; Wang Y; Niggli M; Mohideen P; Wang Y; Foley JE
    Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study.
    Bryrup T; Thomsen CW; Kern T; Allin KH; Brandslund I; Jørgensen NR; Vestergaard H; Hansen T; Hansen TH; Pedersen O; Nielsen T
    Diabetologia; 2019 Jun; 62(6):1024-1035. PubMed ID: 30904939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment.
    Wang N; Zhang JP; Xing XY; Yang ZJ; Zhang B; Wang X; Yang WY
    J Diabetes; 2017 Aug; 9(8):728-737. PubMed ID: 27717194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.
    Kothny W; Lukashevich V; Foley JE; Rendell MS; Schweizer A
    Diabetologia; 2015 Sep; 58(9):2020-6. PubMed ID: 26067186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats.
    Zhang M; Feng R; Yang M; Qian C; Wang Z; Liu W; Ma J
    BMJ Open Diabetes Res Care; 2019; 7(1):e000717. PubMed ID: 31641523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats.
    Zhang Q; Xiao X; Li M; Yu M; Ping F; Zheng J; Wang T; Wang X
    PLoS One; 2017; 12(10):e0184735. PubMed ID: 29036231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
    Li CJ; Yu Q; Yu P; Zhang QM; Ding M; Liu XJ; Yu DM
    Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):469-76. PubMed ID: 24838155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels.
    Zhang JP; Wang N; Xing XY; Yang ZJ; Wang X; Yang WY
    J Diabetes; 2016 Jul; 8(4):559-67. PubMed ID: 26331290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment.
    Gu Y; Wang X; Li J; Zhang Y; Zhong H; Liu R; Zhang D; Feng Q; Xie X; Hong J; Ren H; Liu W; Ma J; Su Q; Zhang H; Yang J; Wang X; Zhao X; Gu W; Bi Y; Peng Y; Xu X; Xia H; Li F; Xu X; Yang H; Xu G; Madsen L; Kristiansen K; Ning G; Wang W
    Nat Commun; 2017 Nov; 8(1):1785. PubMed ID: 29176714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial.
    Foley JE; Bunck MC; Möller-Goede DL; Poelma M; Nijpels G; Eekhoff EM; Schweizer A; Heine RJ; Diamant M
    Diabetologia; 2011 Aug; 54(8):1985-91. PubMed ID: 21547496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice.
    Olivares M; Neyrinck AM; Pötgens SA; Beaumont M; Salazar N; Cani PD; Bindels LB; Delzenne NM
    Diabetologia; 2018 Aug; 61(8):1838-1848. PubMed ID: 29797022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial.
    Han J; Yu H; Tu Y; Pang J; Liu F; Bao Y; Yang W; Jia W
    Diabet Med; 2017 Apr; 34(4):490-499. PubMed ID: 27151271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
    Matthews DR; Paldánius PM; Proot P; Chiang Y; Stumvoll M; Del Prato S;
    Lancet; 2019 Oct; 394(10208):1519-1529. PubMed ID: 31542292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes.
    Bao YQ; Zhou J; Zhou M; Cheng YJ; Lu W; Pan XP; Tang JL; Lu HJ; Jia WP
    Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):564-8. PubMed ID: 20082624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of acarbose therapeutic efficacy in newly diagnosed type 2 diabetes mellitus patients in China.
    Zhang R; Zhao Q; Li R
    BMC Pharmacol Toxicol; 2022 Oct; 23(1):79. PubMed ID: 36258236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.
    Shi L; Zhu J; Yang P; Tang X; Yu W; Pan C; Shen M; Zhu D; Cheng J; Ye X
    Obes Res Clin Pract; 2017; 11(5):607-615. PubMed ID: 28161303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH.
    Li JH; Brenner LN; Kaur V; Figueroa K; Schroeder P; Huerta-Chagoya A; ; ; Udler MS; Leong A; Mercader JM; Florez JC
    Diabetologia; 2023 Jul; 66(7):1260-1272. PubMed ID: 37233759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.